In xenograft models of BRCA-mutant breast cancer, POLθ inhibitor monotherapy suppressed tumor growth, and in 53BP1-deficient, HR-restored tumors, POLθ inhibition resensitized tumors to PARP inhibition [128]. This evidence concerns the gene PARP1 and neoplasm.